Search clinical trials for: CFTR modulators

Total 21582 results

Hospices Civils de Lyon

Not yet recruiting

Circadian Rhythm Disorders in Children With Cystic Fibrosis Under CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Modulators (CHRONO-MUCO)

Cystic Fibrosis

France
Region Stockholm
Karolinska Institutet

Recruiting

CFTR Modulators in Pregnancy and Postpartum

Cystic Fibrosis

Sweden
Oslo University Hospital

Recruiting

Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis

Cystic Fibrosis in Children

Norway
Hospices Civils de Lyon

Recruiting

Muscle Function and Physical Activity in the Modern Era of Cystic Fibrosis (MUCOMUSCLE)

Cystic Fibrosis

France
Assistance Publique - Hôpitaux de Paris

Recruiting

Volatilomic Approaches for the Study of CFTR Modulators (VOLATIL-CF) (VOLATIL-CF)

Cystic Fibrosis

France
Hospices Civils de Lyon

Not yet recruiting

Effectiveness of CFTR Modulators According to Co-therapy (MODUCO)

Cystic Fibrosis
University of Erlangen-Nürnberg Medical School

Recruiting

Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor

Cystic Fibrosis

Germany
Sheffield Teaching Hospitals NHS Foundation Trust

Recruiting

Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis

Cystic Fibrosis

United Kingdom
University of Missouri-Columbia

Recruiting

Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) (SPACE-CF)

Cystic Fibrosis | Mucociliary Clearance Defect

United States
University of British Columbia

Recruiting

Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF (Can-IMPACT CF)

Cystic Fibrosis

Canada
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France

Recruiting

Cystic Fibrosis Blood Neutrophils (MUCO-PNN)

Cystic Fibrosis

France
University of Minnesota

Not yet recruiting

Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers

Pregnancy | Cystic Fibrosis

United States
Amalia Magaret
University of Texas; Cystic Fibrosis Foundation; National Jewish Health

Recruiting

Prospective Study of Pregnancy in Women With Cystic Fibrosis (MAYFLOWERS)

Pregnancy Related | Cystic Fibrosis

United States
Charite University, Berlin, Germany
Hannover Medical School; Heidelberg University; University of Giessen

Recruiting

Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators (Modulate-CF)

Cystic Fibrosis

Germany
Children's Hospital Medical Center, Cincinnati

Recruiting

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials (Nof1)

Cystic Fibrosis

United States
Sonya Heltshe
University of Alabama at Birmingham; University of Washington; Cystic Fibrosis...

Recruiting

Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children (BEGIN)

Cystic Fibrosis

United States
Societe Francaise de la Mucoviscidose

Recruiting

Response to CFTR Modulators in CF Patients Under 18 Years (MODUL-CF)

Cystic Fibrosis in Children

France
Dosentrx Ltd.

Recruiting

Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF).

Cystic Fibrosis | Adherence, Medication

Israel
Jennifer Taylor-Cousar
Cystic Fibrosis Foundation

Recruiting

Impact of Triple Combination CFTR Therapy on Sinus Disease.

Cystic Fibrosis

United States
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

Chronic Rhinosinusitis (Diagnosis)

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study (SIMPLIFY-HS)

Cystic Fibrosis

United States
Indiana University
Cystic Fibrosis Foundation

Active, not recruiting

CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis

Cystic Fibrosis | Bone Loss | Muscle Loss

United States
Hospices Civils de Lyon

Active, not recruiting

Evolution of the 6-minute Walk Test in Patients Treated With ELEXACAFTOR / TEZACAFTOR / IVACAFTOR (TEMETI)

Cystic Fibrosis

France
Qanatpharma Canada LTD

Completed

Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets

Healthy Volunteer

Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI); Vertex Pharmaceuticals Incorporated

Completed

The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor

Chronic Obstructive Pulmonary Disease | Chronic Bronchitis

United States
Universidad Europea de Madrid

Withdrawn

Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis

Cystic Fibrosis in Children

Spain
Hospices Civils de Lyon

Active, not recruiting

Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatment With CFTE Modulators in Children Aged 6 to 11 Years With Cystic Fibrosis With Compatible Mutation (MUCOSINTRIO)

Cystic Fibrosis

France
Children's Hospital Medical Center, Cincinnati

Active, not recruiting

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

Cystic Fibrosis

United States
Children's Hospital Medical Center, Cincinnati
The Hospital for Sick Children; University of Wisconsin, Madison; University...

Active, not recruiting

Hyperpolarized Imaging for New Treatments (HyPOINT)

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Cystic Fibrosis

United States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Ireland
Nottingham University Hospitals NHS Trust

Active, not recruiting

Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior (GIFT-CFJunior)

Cystic Fibrosis

United Kingdom
Nottingham University Hospitals NHS Trust
University of Washington; Seattle Children's Hospital; The Leeds Teaching Hospitals... and other collaborators

Active, not recruiting

CFTR Modulators and Gastrointestinal Complications (CFTR-MAGIC)

Lung Diseases | Cystic Fibrosis | Digestive System Disease | Pancreatic Disease | Distal Intestinal Obstruction Syndrome | Pancreatic Enzyme Abnormality | Gastrointestinal System Disease

United Kingdom
Children's Hospital of Philadelphia
Vertex Pharmaceuticals Incorporated

Completed

Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects

Cystic Fibrosis

United States
University Hospital, Strasbourg, France

Completed

Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor (GLUCORRECTOR)

Cystic Fibrosis Homozygous for Phe 508 Del CFTR | Glucose Intolerance or Newly Diagnosis Diabetes

France
Parion Sciences
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United Kingdom, United States, France, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States
Carmel Medical Center

Completed

Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients.

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) (VOCAL)

Cystic Fibrosis

Netherlands, Italy, United Kingdom
Vertex Pharmaceuticals Incorporated

Terminated

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Hannover Medical School
Heidelberg University; University of Giessen

Completed

ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor (OrkambiFacts)

Cystic Fibrosis

Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

Cystic Fibrosis

Israel
Forest Laboratories

Completed

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder (VLZ-MD-21)

Major Depressive Disorder

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

Australia, United Kingdom
Richard Barry Moss

Completed

(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France

Search clinical trials for: CFTR modulators

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations